Bundesunterstützung Swiss Vaccine Research Institute

• Forschungsstelle: SBFI
• Projektnummer: P2021-SVRI

Schlüsselwörter (Englisch)

Vaccine, Immunology, Infections diseases, Cancer, Malaria, Tuberculosis, HIV/AIDS

Forschungsprogramme (Englisch)

The SVRI (ISRF) will encompass major facets of basic, clinical and translational research covering predominantly the three major infectious diseases:

• HIV/AIDS
• malaria
• tuberculosis

as well as the emerging influenza pandemic threat.

The SVRI will also benefit from ongoing efforts in the area of cancer vaccine research.

Kurzbeschreibung (Englisch)

The SVRI will be based initially on the partnership between the following leading institutions, based in different parts of Switzerland:

1. Centre Hospitalier Universitaire Vaudois (CHUV)
2. Université de Lausanne/Faculté de Biologie et de Médecine (UNIL/FBM)
3. Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne
4. Institute for Research in Biomedicine (IRB), Bellinzona
5. Ludwig Institute for Cancer Research (LICR), Lausanne Branch, Epalinges
6. Swiss Tropical and Public Health Institute (Swiss TPH), Basel

 

These six institutions have a long tradition and a concentration of scientists in the fields of immunology, of HIV, malaria, TB and cancer vaccine development, of virology and of adjuvant/delivery technology. Partnerships with other Swiss institutions competent in the fields of immunology and vaccines will be strongly favoured.

The SVRI is driven by the common goal of international initiatives promoted at a political, corporate and academic level to reduce or eliminate suffering and death due to infectious diseases and cancer.

The SVRI will contribute to this goal through exploration, scientific discovery and translation of the discoveries into effective preventive vaccine strategies and therapeutic vaccine interventions for infectious diseases and for cancer.

Projektziele (Englisch)

On the basis of the expertise existing at the CHUV/UNIL, EPFL, IRB and LICR, the SVRI will have the structure of a multi-site organisation.

The institutions located in Lausanne will develop the programme on two sites: the CHUV-Bugnon/Ludwig Institute for Cancer Research-Epalinges site, and  the EPFL-Ecublens site:

1. The CHUV (http://www.immunologyresearch.ch/) will conduct translational research and immunology programmes aiming at identifying protective immune correlates and developing standardized laboratory platforms for the assessment of immune responses. In addition, the CHUV will provide the infrastructures for conducting clinical trials.
2. The EPFL (http://sv.epfl.ch/page-26568-en.html) will conduct the fundamental research programmes in virology, microbiology and vectorology. Moreover, the proximity on site of robotics and micro-technique specialists will be very important for the development of new, high flow and automated immunology tests. The EPFL will also put at the SVRI’s disposal its principal infrastructures for proteomics, microscopic imagery, biomedical imagery, protein production, genomics and for high flow biomolecular screening.
3. The Institute for Research in Biomedicine (IRB) in Bellinzona (http://www.irb.ch/) will conduct a fundamental research programme in immunology, aiming at characterizing T-cell memory as well as analyzing the mechanisms causing T-cell responses.
4. The Ludwig Institute for Cancer Research-Lausanne ( http://www.ludwigcancerresearch.org/location/lausanne-branch) will also conduct a fundamental and translational research programme in immunology aiming at developing novel strategies for clinically effective vaccination of cancer patients. It will also participate in the joint efforts of the SVRI to develop standardized assays for the monitoring of T and B-cell responses in human subjects.

Projektziele (Französisch)

L'Institut Suisse de de Recherche sur le Vaccin fait partie des organismes de recherche subventionnés par la Confédération, et cela selon les critètres définis dans la loi sur la recherche http://www.admin.ch/ch/f/rs/c420_1.html

Abstract (Englisch)

For further information visit the Swiss Vaccine Research Institute (SVRI) website at:
http://www.swissvaccineresearchinstitute.ch/

Contact:
Swiss Vaccine Research Institute
c/o Centre Hospitalier Universitaire Vaudois
Rue du Bugnon 46
CH-1011 Lausanne
Tel [phone]
[e-mail]